Navigation Links
Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Date:3/2/2009

SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB) today announced that an Independent Data Monitoring Committee (IDMC) has completed a planned, pre-specified safety review of interim data from the ongoing pivotal rALLy clinical trial of Marqibo(R) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The results of the IDMC review continue to support the acceptable safety profile observed with Marqibo in earlier studies and no new safety concerns were identified. The IDMC has recommended that the trial continue to completion per protocol.

The Company has accrued 42 patients, or 75 percent, of the total target enrollment of 56 evaluable patients. Recruitment is on target to complete in mid-2009. Results of the Company's planned interim efficacy analysis are forthcoming.

"The IDMC's recommendation to continue the rALLy trial represents an important milestone in the development of Marqibo and towards our goal of developing a therapeutic for this very sick patient population," stated Anne Hagey, M.D., vice president and chief medical officer of Hana Biosciences. "Thanks to our enthusiastic and committed investigators, patient enrollment remains on track. We target The 2009 American Society of Hematology Annual Meeting for a complete data presentation and look forward to submitting a New Drug Application for accelerated approval of Marqibo in 2010."

The interim analysis was designed to assess the safety data of the trial collected to date and also focus on logistical issues such as accrual, retention, and quality of clinical and laboratory data. This interim assessment was based upon a planned evaluation of safety data from the first 29 patients in the study who received at least one c
'/>"/>

SOURCE Hana Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Medical - SECRITT I Study to Evaluate Preventive Treatment ... Potentially Life Threatening Vulnerable Plaques, ... cardiology team led by Professor Patrick W. Serruys,successfully placed ... coronary artery of a 64-year-old man at Erasmus Medical,Center ...
... -- 10:00 a.m. EDT, 7:00 a.m. PDT ... -- 877-548-7901 ... http://www.isispharm.com , SAN DIEGO, June 30 Isis Pharmaceuticals,(Nasdaq: ISIS ) will conduct a ... TV-1102 clinical trial,and the ATL / TEVA / Isis relationship., -- ATL and TEVA announced clinical ...
Cached Medicine Technology:Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3Isis Pharmaceuticals Conference Call Notice 2
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
(Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
(Date:4/17/2014)... Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work has transformed ... a Fellow of the European Academy of Cancer Sciences., ... independent advisory body of highly distinguished oncologists and cancer ... caused by cancer in Europe. , Professor Johnston, whose ... move from the bottom of the UK league table ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
(Date:4/16/2014)... that fertility treatments are the leading cause of increases ... risk of premature birth, these results are not inevitable, ... . The article identifies six changes in policy ... births and prematurity, including expanding insurance coverage for in ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... Inc. (Nasdaq: SMBL ) announced today Steven Hughes, ... make a presentation at the Roth Capital Partners 21st Annual ... EST on Tuesday, February 17, 2009.Smart Balance,s presentation will be ... be able to ask questions, but listeners to the webcast ...
... from the clinical research community have already pledged ... American National Standards Institute (ANSI), coordinator ... is working to facilitate the use of electronic ... The Institute seeks the active engagement and financial ...
... Feb. 13 Dynatronics Corporation (Nasdaq: DYNT ) ... months ended December 31, 2008. Operating results showed significant improvement ... Pre-tax profit for the quarter ended December 31, 2008, improved ... the second quarter of the prior fiscal year. Net income ...
... BETHESDA, Md., Feb. 13 Micromet, Inc. (Nasdaq: MITI ), ... the ROTH 21st Annual Orange County Growth Stock Conference at the Ritz-Carlton ... The ROTH 21st Annual Orange County Growth Stock Conference, ... 4:30 pm Pacific Time, Place: The Ritz-Carlton ...
... SAN FRANCISCO, Feb. 13, 2009 New techniques used ... in the wild are yielding surprising results about hormones ... the social structure of a broader range of mammals. ... present findings at the AAAS meeting that examine social ...
... Applauds Senator Rockefeller and Representative Filner for Introducing ... Federation of Government Employees (AFGE) today applauded the ... the Senate Committee on Veterans, Affairs and Representative ... Veterans, Affairs for authoring legislation to amend Section ...
Cached Medicine News:Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 2Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 3Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 4Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 2Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 3Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 4Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 2Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 3Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 4Health News:Findings raise new questions about evolution of hormones in mammals 2Health News:Veterans' Affairs Employee Union Urges Congress to Strengthen Collective Bargaining Rights at VA Hospitals 2
... ML1 Manual Lensometer combines the traditional ... advantages, such as LED illumination and ... light source provides a clear green ... operated and completely cordless, the ML1 ...
... The Ultramatic RX Master Phoroptor ... - continues to be the industry standard ... that unmistakable feel of quality. The smooth ... of play in the mechanisms. The precise, ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
Medicine Products: